Lab work may be ordered to evaluate metabolic health, blood sugar levels, and hormone balance
Alexeev M, Grosenbaugh DK, Mott DD, Fisher JL
Not every patient is an appropriate candidate for GLP-1 therapy, regardless of demand
The problem is variability: not all compounders meet that standard, and patients often cannot easily verify which ones do
It claimed 'GLP-1s for diabetes could be sold at a profit for just US $0.89 per month, compared to the price of $95 per month charged in Brazil, $115 per month charged in South Africa, $230 charged in Latvia and $353 charged in the US, which is a 39,562% markup over what the estimated generic price could be.' Christa Cepuch, Pharmacist Coordinator at MSF's Access Campaign, argues 'These new drugs are an absolute game changer for people living with diabetes, but are being kept out of the hands of hundreds of millions of people in low- and middle-income countries who need them' (Barber, Gotham, Bygrave